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Selective Reduction of Heart Rate with the Sinus
Node Inhibitor Zatebradine (ULFS 49) Does not Lead
to the Expected Improvements in Exercise Duration
in Patients with Angina Pectoris
Stephen P. Glasser, David Michie, Udho Thadani, Wolfgang M. Baiker, Zatebradine
Investigators I. University ofSouth Florida, Tampa, FL
Zatebradine is a novel compound blocking selectively the iF-channel in the
sinus node, which is believed to be the pacemaker current. Its effect on
heart rate is believed to be very selective, without any other effects on the
myocardium. Since it is widely believed that the beneficial effects of beta-
blockers are due to their heart rate reducing properties, selective reduction
of heart rate without negative inotropy should result in prolongation of exer-
cise duration and reduction in myocardial ischemia in patients with angina
pectoris. To investigate this hypothesis we performed a multicenter, random-
ized, double-blind, placebo-controlled, dose ranging study with zatebradine.
Patients (n-237) with reproducible exercise induced angina pectoris with evi-
dence of myocardial ischemia (?: 1 mm ST-segment depressionI received ei-
ther placebo, 2.5, 5.0 or 7.5 mg zatebradine for 4 weeks. Symptom limited
exercise tests were repeated at 3 and 12 hours post dose after 4 weeks of
treatment.
Change Placebo Zatebradine
from 3 h pa 12 h pa 2.5 mg 5.0 mg 7.5 mg
Baseline
12 h pa 3 h pa 12 h pa3h 12 h 3 h pa
Total ETD 30 30 33 25 42 28 50 38
(s)
Time 1 Min 24 34 27 33 57' 34 57 ' 48
(s)
HR Rest 1.8 0.5 -6.4*** -6.2**- ~12.1*** -8.0**· -20.5**· -13.7***
(bpm)
HR Ex 3.8 3.8 -5.9**· -5.5*** ~ 10.9*** -9.6*** -19.2**· -14.4***
(bpm)
EXSBP -2.3 -04 6.4*'" 3.2 5.4' 4.1 3.4 60
(mmHg)
h = hours, p.a. = post administration,s = seconds.•p< 0.05. **p< 0.01, ***p< 0.001,
ETD = exercise test duration, HR = heart rate. EX = Exercise, SSP = Systolic Blood
Pressure
Conclusion: Zatebradine is a powerful agent that reduces heart rate dose-
dependently over at least 12 hours. The observed heart rate reduction did not
translate into the expected improvements of exercise performance or reduc-
tion of myocardial ischemia suggesting that the anti-ischemic effect of heart
rate limitation should be reconsidered.
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1723-21 Selective Antagonism of Adenosine A1 Receptor
Mediated Effects in Humans with N-0861 ,
(N6-Endonorboran-2-yl-9-Methyladenine)
Barry D. Bertolet, Elizabeth A. Franco, Richard A. Kerensky, Wilmer W. NiChols,
Luiz Belardinelli, James A. Hill. University of Florida, Gainesvlile, FL
To determine the receptor subtype selectivity of the novel A1-adenosine
(ADO) receptor (R) antagonist, N-0861, the A1 and A2 R-mediated cardiac
effects were investigated in 13 patients during continuous Lv. infusion and
boluses of ADO before and after Lv. infusion of N-0861. Also, we sought to
determine the effects of N-0861 on ADO-induced chest pain.
Methods: Measurements of A-H interval (A1 effect), and coronary blood
flow velocity (CBFV) (A2 effect) were made before and after low dose (70
",g/kg) i.v. infusion and bolus (3 mg) ADO. N-0861 (0.25 mglkg) was infused
and the protocol repeated. At each stage, patients rated any chest discomfort
from 0 (no pain) to 10 (very severe pain) using a Borg Pain Scale.
Results: No adverse effects of N-0861 were noted. No evidence of myocar-
dial ischemia occurred during any part of the protocol. Chest discomfort oc-
curred in 11 patients and was transient, ending shortly after the ADO infusion
was terminated.
°expressed as percent increase over baseline;
*p < 0.05 compared to ADO alone
N-0861 abolishes the negative dromotropic effect and chest discomfort ex-
perienced during infusion of ADO, and attenuated discomfort observed dur-
ing the boluses of ADO.
Conclusions: 1) These actions of N-0861 support the conceptthat the neg-
ative dromotropic effect and angina-like pain caused by ADO are A1-ADO R
mediated; whereas, the increase in CBFV is due to activation of A2-ADO R's.
2) N-0861 appears to be an effective and selective A1-ADO R antagonist in
man. 3) In the presence of N-0861, ADO is a selective short-acting A2 sub-
type R agonist.
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1723-31 Endothelin in the Skin Microcirculation of Patients
with Coronary Heart Disease: Effect of Endothelin
Antagonist and Calcium Antagonist
Rene R. Wenzel, Georg Noll, Nadine Duthiers, Thomas F. Luscher. Cardiology,
University Hospital, Bern, Switzerland
Endothelin, a potent vasoconstrictor peptide released from endothelial cells,
is elevated in different cardiovascular diseases, I.e. atherosclerosis, acute
myocardial infarction, diabetes mellitus and pulmonary hypertension. The ef-
fects of the ETA-endothelin receptor antagonist PO 147953 (PD; 10-8 mol)
and the calcium-antagonist diltiazem (D; 10-7 mol) on endothelin-1 (ET;
10-12 mol) induced changes in blood flow of skin microcirculation were stud-
ied in 10 patients (7 male, 3 female) with angiographically documented coro-
nary heart disease (CHD) and in 10 healthy controls with a newly developed
double injection model. Changes in blood flow were assessed with laser-










., PalI.nll with CHO Healthy controls
(AUe: area under curve of changes in arbitrary perfusion units CPU)
over 30 min: '/"·p<O.05/0.001 vs 8, *p<0.05 vs controls)
Conclusions: In patients with CHD, the vasoconstriction to endothelin-1 is
reduced compared to healthy young controls.
The calcium-antagonist diltiazem inhibits endothelin induced vasocon-
striction in healthy volunteers and in patients with CHD. The endothelin-
antagonist PO 147953 fully prevents endothelin-induced vasoconstriction in
the skin microcirculation of patients with CH 0 in a 10 times lower concentra-
tion than the calcium antagonist.
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1723-4\ Cardiovascular and Neurohormonal Effects of SDZ
WAG 994, a Selective Adenosine A1 Receptor
Agonist, in Man
Inder Anand, Y. Chandrashekhar, Anne McCauley, Susan Ziesche, Michelle Berg,
Dianne Judd, Nardev Khurmi, Jay N. Cohn. VA Medical Center & University of
Minnesota, Minneapolis
Adenosine is the treatment choice for paroxysmal supraventricular tachycar-
dia (PSVT). However, short half life and lack of an oral preparation limits its
use. SDZ WAG 994 is a new orally active selective adenosine A1 receptor
agonist. Its rapid action and sustained effect (6 - 8 hr) might be advanta-
geous in the treatment of PSVT. It also produces presynaptic inhibition of
norepinephrine release but its effects in man have never been tested. We in-
vestigated the effects of oral administration of 2 & 5 mg SDZ WAG 994 on
exercise parameters -Iheart rate - HR, blood pressure, Anaerobic Thresh-
old, Peak V02 &Ventilatory indices) &Neurohormones in 12 normal subjects
in a single blind, placebo baseline-controlled, dose escalating design. SDZ
WAG 994 did not affect resting HR but the 2 mg dose caused a decrease
in peak exercise HR (by 11 beatslmin, p < 0.01). The 5 mg dose had no fur-
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1723-61 Hemodynamic Effects of Graded Oral Doses of a New
Dopaminergic Analogue CHF 1035 In Patients with
Congestive Heart Failure
lACC February 1995
5 mg 10 mg 15 mg
PD AD PD AD PD AD
PCWP 22 ± 5 18 ± 4* 20 ± 6 16 ± 9* 21 ± 7 16 ± 6*
CI 3± 1 3.4 ± 1* 2.7 ± 1 3.4 ± 1* 3±1 4 ± 1*
SVI 39 ± 12 43 ± 11 38± 7 45 ± 10* 40± 10 49 ± 11*
SVR 1243 ± 27 1052 ± 265 1382 ± 45 1009±315 1359 ± 36 881 ± 257*
HR 74 ± 11 78 ± 11* 70 ± 11 76 ± 12 74 ± 12 80 ± 10*
8Pm 85 ± 12 82 ± 12 85 ± 10 77 ± 13* 87 ± 11 79 ± 12*
NE 299 ± 135 301±156 285 ± 244 244 ± 88* 340 ± 162 308 ± 133
E 56 ± 29 42 ± 21* 65 ± 42 62 ±44 53 ± 25 58 ± 24
*: p < 005
No changes in hemodynamic or neurohormonal parameters occurred af-
ter P administration. Our results demonstrate that CHF 1035 induce a signifi-
cant improvement in hemodynamic parameters in pts with CHF. In particular
it is able to induce systemic vasodilatation without any reflex increase in cate-
cholamine plasma levels. Thus CHF 1035 appears to be a promising drug for
the treatment of CHF.
Transcatheter treatment of atrioventricular nodal reentrant tachycardia
(AVNRT) modifies but frequently does not eliminate the electrophysiologic
substrate for reentry. The extent of modification required thus remains un-
clear. High recurrence rates have been reported when single AV nodal echos
(AVNe) remain inducible. We, therefore, prospectively evaluated the charac-
teristics of AVNe pre and postAV nodal modification.
Results: Ablation was deemed successful when sustained AVNRT could
not be induced on isoproternol (ISO). After successful ablation, AVNe was in-
ducible in 24 pts and noninducible in 72 pts. Other electrophysiologic param-
eters in these two groups were comparable with similar increases in 1: 1 AV
block cycle lengths (356 to 413 and 368 to 400 msec, p < 0.005) and AVNERP
(258 to 317 and 264 to 313 msec, p < 0.001) pre to post ablation. In Group 1
patients, persistent AVNes following successful ablation (good echoes) were
associated with an increase in AH interval in all but one patient as compared
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Electrophysiologic Endpoints of Successful
Radlofrequency Catheter Modification for
Atrioventricular Nodal Reentrant Tachycardia. Are
There "Good" and "Bad" Persistent Echoes?
Anwer Dhala. Zalmen Blanck, Margaret Budziszewski, Michael Biehl,
Sanjay Deshpande, Jasbir Sra, Mohammad R. Jazayeri, Masood Akhtar. Sinai
Samaritan/St. Luke'5 Medical Center, Milwaukee, WI
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1724-1 1Characteristics of Successful Posterior Septal Sites
to Cure Atrioventricular Node Reentry Using a
Thermistor Controlled Catheter System
Rafe Chamberlain Webber, John N. Hill, Joseph J. Evans, Richard I. Fogel, Eric
N. Prystowsky. Indiana Heart Institute, Indianapolis, IN
We prospectively investigated in 55 pts characteristics of successful radiofre-
quency ablation (RFA) sites to cure AVN reentry (AVNRT) using a thermistor
tipped catheter system with a posterior (slow pathway) approach. RFA suc-
cess (SI was :0:2 AVNRT echos after RFA; only 1 pt had AVNRT at follow-up.
There were 166 RFA [55 S; 111 failure (F)], with 3 ± 3/pt. Local atrial electro-
gram morphology was-A (low to isoelectric to high frequency); B (low to
high frequency); and C (:::2 high frequency components). Differences with S
vs F, respectively. are: atrial amplitude (396 ± 181 vs 357 ± 205 /Lv' P < 0.001);
ventricular amp. (3.0 ± 1.6 vs 2.7 ± 1.6 mV, p < 0.001); time to onset of junc-
tional tachycardia (JT) (2.1 ± 1.9 vs 4.6 ± 6.1 sec, p < 0.05); duration of JT
1146 ± 8.6 vs 11.6± 7.7 sec, p < 0.001); CL ofJT(481 ± 92vs 511 ± 120
ms, p < 0.0011; and change in CL of JT during RFA (-34 ± 113 vs +23 ± 128
ms, p < 0.03). Of note, continuous JT was more common at S sites (46% vs
21 %), and JT occurred in :0:7.5 sec at all S sites. No differences between Svs
F were in: power(46.8 ± 7.5 vs 44.5 ± 8.6 W); catheter tip temp. (52.6 ± 4.6
vs 49.3 ± 5.5"C); atrial electrogram duration (66 ± 20 vs 66 ± 19 ms); ortype
of local atrial electrogram. We conclude: 11 Successful RFA to cure AVNRT
more frequently occurs with rapid onset of continuous junctional tachycardia
with a CL that shortens before termination and, 2) there is no specific local
atrial electrogram morphology that predicts success.
ABSTRACfS
ther effect. There was a 16 msec increase in the PR interval at rest with 2 mg
(159 to 175 msec, P < 0.01) with no further change at 5 mg. The increase in
PR persisted even during peak exercise (115, 134 & 149 msec with placebo.
2 &5 mg, P < 0.001). The drug had no effect on resting &exercise blood
pressure, exercise time, V02, anaerobic threshold, ventilatory indices, and
epinephrine, norepinephrine or aldosterone at peak exercise. However. SDZ
WAG 994 completely suppressed the normal increase in plasma renin activ-
ity(PRA) with exercise (P < 0.01). An interesting and unexpected finding was
a dose-dependent increase in ANF seen both at rest and peak exercise (P <
0.01). These findings suggest that a single dose of this oral adenosine A, se-
lective agonist, has the expected negative chronotropic &dromotropic prop-
erties in man, even during exercise when circulating catecholamines were
very high (epinephrine 299 ± 220 pg/ml, norepinephrine 1947 ± 998 pg/ml)
without any adverse cardiovascular effects. Its effects on PRA &ANF suggest
that SDZ WAG 994 may also be an important neurohormonal modulator in
man.
Carmine Morisco, Bruno Ricciardelli, Luigi Argenziano, Virgilio Rendina,
Guido laccarino, Carmine Vecchione, Alberto Umile 1, Massimo Volpe
Bruno Trimarco. I Clinica Medica Universita "FEDERICO II" Napoli, Italy; i Chiesi
Farmaceutici s.p.A., Italy
We investigated in a randomized double-blind study the hemodynamic ef-
fects of 3 single oral doses (5, 10 and 15 mg) of a new dopaminergic ana-
logue (CHF 1035) VS placebo (P) in 18 patients (pts) with congestive hea rt fail-
ure (CH F) (ejection fraction 25 ± 7%). Each patient received on 3 consecutive
study-days 2 active doses of CHF 1035 and 1 Pdose. The following measure-
ments were performed using a Swan-Ganz catheter pre-dose (PO) and from
20 to 300 min after dosing (AD) levery 20 min for the first 2 hours, then ev-
ery 60 min): pulmonary capillary wedge pressure (PCWP) (mmHg), cardiac
index ICI) (I/min/m2), stroke volume index (ml/min/m2), systemic vascular re-
sistance (SVR) (dyne. sec· cm-5), heart rate (HR) Ibpm). mean blood pressure
(BPm) (mmHg). Plasma levels of norepinephrine (NE) (pg/ml) and epinephrine
(E) (pg/ml) were also assessed before and 140 min after CHF 1035 or P ad-
ministration. The hemodynamic (peak value) and neurohormonal parameters
showed the following changes after CHF 1035 administration.
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Evaluation of the Antianginal and Anti-ischemic
Effects of the Sinus Node Inhibitor Zatebradine Used
in Combination with Extended-Release Nifedipine In
Patients with Angina Pectoris
William Frishman, Carl Pepine, Robert WeiSS, Wolfgang Baiker, Zatebradine
Multicenter Study Group. Albert Einstein College ofMedicine, Bronx, NY
Zatebradine (Z) is a directsinus node inhibitor which is orally active and, unlike
p-adrenergic blockers, has no effect on blood pressure, vascular resistances,
and ventricular contractility. We evaluated the anginal and anti-ischemic ef-
fects of Z 15 mg administered twice daily) and placebo in 124 patients (pts)
already receiving 3D-90 mg of extended-release nifedipine once daily, whose
treadmill exercise tolerance was still limited. After 2-3 wks of single-blind
placebo therapy with reproducible exercise-induced angina on the treadmill,
pts were randomized to receive in double-blind fashion twice daily Z (n = 64)
or twice daily placebo (n = 60) in addition to nifedipine. Subjects were fol-
lowed with serial exercise tests 13 hrs post dose) for 4 wks and angina diaries
were maintained. At 4 wks, Z was shown to reduce resting heart rate (HR) in
contrast to placebo (12.9 ± 1,23 vs 2.3 ± 1.6 bpm, p < 0.0001), and at the
end of comparable stages of exercise (Bruce). Z reduced HR in contrast to
placebo (16.7 ± 1.2 vs 3.4 ± 1.2 bpm, p < 0.001). Despite these significant
effects on HR with Z at rest and exercise, there were no additional antiang-
inal benefits of Z from placebo baseline in measurements of total exercise
duration, time to 1 mm ST segment depression, or time to onset of angina.
Z appears to provide no additional antianginal benefit to pts already receiving
nifedipine, and raises questions regarding the benefit of HR reduction alone
as an antianginal approach in pts.
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